Cancer vanishes from every patient’s body in drug trial



ANI |
Updated:
08 June 2022 08:09 IST

New Delhi [India]June 8 (ANI): In what seems like a miracle and “the first in history,” a small clinical trial showed that every rectal cancer patient who received an experimental treatment found their cancer was gone.
According to the New York Times, 18 patients in the small clinical trial conducted by Memorial Sloan Kettering Cancer Center took the drug Dostarlimab for about six months, and they all eventually saw their tumors disappear.
dr. Luis A. Diaz J. of Memorial Sloan Kettering Cancer Center in New York said this was “the first time in cancer history.”
According to experts, Dostarlimab is a drug with lab-produced molecules and acts as replacement antibodies in the human body.
The cancer is not detectable by physical examination; endoscopy; positron emission tomography or PET scans or MRI scans, added Experts. This proves that dostarlimab may be a ‘possible’ cure for one of the most deadly cancers.
According to the New York Times, patients involved in the clinical trial previously underwent treatments such as chemotherapy, radiation and invasive surgery that can lead to bowel, urinary and even sexual dysfunction. The 18 patients entered the study expecting to go through these procedures as the next step. To their surprise, however, no further treatment was required.
The findings of this study have shocked experts, and they have pointed out that complete remission is “unheard of” in any single patient.
dr. Alan P. Venook, a colorectal cancer specialist at the University of California, said complete remission in every single patient is “unheard of.” He praised the research as a “world first”.
Experts said the study was impressive, as not all patients experienced significant complications from the drug trial.
“There were many happy tears,” said oncologist Dr. Andrea Cercek, who described the moment patients discovered they were cancer-free, as quoted by the New York Times.
According to doctors, the patients took Dostarlimab every three weeks for six months. “It is noteworthy that they were all in similar stages of their cancer. The cancer had advanced locally in the rectum, but had not spread to other organs,” doctors added.
“At the time of this report, no patients had received chemoradiation or surgery, and no cases of progression or recurrence had been reported during follow-up,” researchers wrote in the study, which was published in the media.
Cancer researchers who reviewed the drug told the media that the treatment looks promising, but that a larger-scale study is needed. (ANI)

Leave a Comment

Your email address will not be published.